Dermata Therapeutics (NASDAQ:DRMA) Stock Jumps 0.5% – Here’s What Happened

Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) shares traded up 0.5% during mid-day trading on Monday. The company traded as high as $1.16 and last traded at $1.11. 14,095 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 23,695 shares. The stock had previously closed at $1.1050.

Analyst Ratings Changes

Separately, Weiss Ratings raised Dermata Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Dermata Therapeutics presently has a consensus rating of “Sell”.

Get Dermata Therapeutics alerts:

Check Out Our Latest Analysis on DRMA

Dermata Therapeutics Stock Performance

The stock’s fifty day moving average price is $1.25 and its 200-day moving average price is $1.27. The firm has a market cap of $4.50 million, a PE ratio of -0.26 and a beta of 0.66.

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.19).

About Dermata Therapeutics

(Get Free Report)

Dermata Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological diseases and conditions. The company’s research is centered on topical therapies designed to address unmet needs in areas such as acne, psoriasis and other inflammatory or medical skin disorders.

Dermata’s lead product candidate, DMT310, is a topical treatment platform being investigated for conditions including acne vulgaris and plaque psoriasis. The company has also developed additional topical product candidates, including DMT410, which has been studied for dermatological conditions involving excessive sweating.

Further Reading

• Five stocks we like better than Dermata Therapeutics
• Could Velo3D Be the Next Defense Buyout Target?
• Penguin Solutions Is Soaring as AI Memory Demand Explodes
• Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
• Morgan Stanley Is Bullish on Apple—But With a Catch

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.